Skip to content

White House and Congress Must Boldly Address Drug Pricing and Ensure Access to Critical HIV, HCV, and TB Medications

  • Chad Cipiti

Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.

Read more

TAGline Spring 2018

  • Chad Cipiti

Bend the Curves: Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible.

Read more

Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV

  • Chad Cipiti

The purpose of this Training Manual is to provide information for you and your community. This information can be used to advocate for access to prevention and diagnosis of, and care and treatment for, hepatitis C virus (HCV). The manual is written by and for people who are not medical specialists. We’re treatment activists who learned about HCV because it was a problem for people in our communities.

Read more

Forging A Path to HCV Elimination: Simpler Tests and Affordable Generics

  • Chad Cipiti

In July 2017, 37 treatment activists from 17 countries—including 14 low- and middle-income countries (LMICs)—met with representatives from three generics and three diagnostics companies. This Hepatitis C World Community Advisory Board meeting was an opportunity for activists to present demands…

Read more
Back To Top